istock-508859346_walterbilotta-1

walterbilotta/ iStockphoto.com

10 November 2017Big Pharma

LSIPR 50 2017: Sean Dennehey—Steering the ship

2016 was a tumultuous year. Not only did the UK vote to leave the EU, but the UK Intellectual Property Office (IPO) lost its CEO and two experienced directors.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Teva fights for re-listing of inhaler patents at US appeals court

White & Case hires experienced litigator from A&O Shearman